18F-choline
Hyperparathyroidism
PET/CT
PET/MRI
Systematic review
Journal
Annals of nuclear medicine
ISSN: 1864-6433
Titre abrégé: Ann Nucl Med
Pays: Japan
ID NLM: 8913398
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
22
06
2020
accepted:
26
07
2020
pubmed:
9
8
2020
medline:
8
6
2021
entrez:
9
8
2020
Statut:
ppublish
Résumé
The aims of the present systematic review were to: (1) assess the role of
Identifiants
pubmed: 32767248
doi: 10.1007/s12149-020-01507-1
pii: 10.1007/s12149-020-01507-1
pmc: PMC7438295
doi:
Substances chimiques
fluoromethylcholine
0
Choline
N91BDP6H0X
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
601-619Références
Hindié E, Ugur O, Fuster D, O’Doherty M, Grassetto G, Ureña P, Kettle A, Gulec SA, Pons F, Rubello D. Parathyroid Task Group of the EANM, 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009;36:1201–16. https://doi.org/10.1007/s00259-009-1131-z .
doi: 10.1007/s00259-009-1131-z
pubmed: 19471928
Delellis RA, Mazzaglia P, Mangray S. Primary hyperparathyroidism: a current perspective. Arch Pathol Lab Med. 2008;132:1251–62. https://doi.org/10.1043/1543-2165(2008)132%5b1251:PHACP%5d2.0.CO;2 .
doi: 10.1043/1543-2165(2008)132[1251:PHACP]2.0.CO;2
pubmed: 18684024
Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? World J Surg. 2007;31:916–23. https://doi.org/10.1007/s00268-006-0837-3 .
doi: 10.1007/s00268-006-0837-3
pubmed: 17345120
Amadou C, Bera G, Ezziane M, Chami L, Delbot T, Rouxel A, Leban M, Herve G, Menegaux F, Leenhardt L, Kas A, Trésallet C, Ghander C, Lussey-Lepoutre C.
doi: 10.1007/s00268-019-04910-6
pubmed: 30659347
Reid LJ, Muthukrishnan B, Patel D, Seckl JR, Gibb FW. Predictors of nephrolithiasis, osteoporosis, and mortality in primary hyperparathyroidism. J Clin Endocrinol Metab. 2019;104:3692–700. https://doi.org/10.1210/jc.2018-02483 .
doi: 10.1210/jc.2018-02483
pubmed: 30916764
Collier A, Ghosh S, Nowell S, Clark D. Increased mortality in patients with primary hyperparathyroidism: does surgery make a difference? Endocr Pract. 2019;25:335–9. https://doi.org/10.4158/EP-2018-0407 .
doi: 10.4158/EP-2018-0407
pubmed: 30995426
Ciappuccini R, Morera J, Pascal P, Rame J-P, Heutte N, Aide N, Babin E, Reznik Y, Bardet S. Dual-phase 99mTc sestamibi scintigraphy with neck and thorax SPECT/CT in primary hyperparathyroidism: a single-institution experience. Clin Nucl Med. 2012;37:223–8. https://doi.org/10.1097/RLU.0b013e31823362e5 .
doi: 10.1097/RLU.0b013e31823362e5
pubmed: 22310246
Evangelista L, Zattoni F, Guttilla A, Saladini G, Zattoni F, Colletti PM, Rubello D. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38:305–14. https://doi.org/10.1097/RLU.0b013e3182867f3c .
doi: 10.1097/RLU.0b013e3182867f3c
pubmed: 23486334
Quak E, Lheureux S, Reznik Y, Bardet S, Aide N. F18-choline, a novel PET tracer for parathyroid adenoma? J Clin Endocrinol Metab. 2013;98:3111–2. https://doi.org/10.1210/jc.2013-2084 .
doi: 10.1210/jc.2013-2084
pubmed: 23788686
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60. https://doi.org/10.1136/bmj.327.7414.557 .
doi: 10.1136/bmj.327.7414.557
pubmed: 192859
pmcid: 192859
Moher D, Liberati A, Tetzlaff J, Altman DG, DPRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9. https://doi.org/10.7326/0003-4819-151-4-200908180-00135 .
doi: 10.7326/0003-4819-151-4-200908180-00135
Michaud L, Burgess A, Huchet V, Lefèvre M, Tassart M, Ohnona J, Kerrou K, Balogova S, Talbot J-N, Périé S. Is 18F-fluorocholine-positron emission tomography/computerized tomography a new imaging tool for detecting hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism? J Clin Endocrinol Metab. 2014;99:4531–6. https://doi.org/10.1210/jc.2014-2821 .
doi: 10.1210/jc.2014-2821
pubmed: 25215560
Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, Lefèvre M, Tassart M, Montravers F, Périé S, Talbot J-N. A pilot comparison of
doi: 10.1097/MD.0000000000001701
Kluijfhout WP, Pasternak JD, Gosnell JE, Shen WT, Duh Q-Y, Vriens MR, de Keizer B, Hope TA, Glastonbury CM, Pampaloni MH, Suh I.
doi: 10.1148/radiol.2016160768
pubmed: 28121522
Prabhu M, Kumari G, Damle NA, Arora G, Kumar P, Kumar R, Tripathi M, Bal C, Khadgawat R, Kumar C, Agarwal S. Assessment of the role of early dynamic PET/CT with
doi: 10.1097/MNM.0000000000000924
pubmed: 30379751
Kluijfhout WP, Vorselaars WMCM, van den Berk SAM, Vriens MR, Borel Rinkes IHM, Valk GD, van Dalen T, de Klerk JMH, de Keizer B. Fluorine-18 fluorocholine PET-CT localizes hyperparathyroidism in patients with inconclusive conventional imaging: a multicenter study from the Netherlands. Nucl Med Commun. 2016;37:1246–52. https://doi.org/10.1097/MNM.0000000000000595 .
doi: 10.1097/MNM.0000000000000595
pubmed: 27612033
Quak E, Blanchard D, Houdu B, Le Roux Y, Ciappuccini R, Lireux B, de Raucourt D, Grellard J-M, Licaj I, Bardet S, Reznik Y, Clarisse B, Aide N. F18-choline PET/CT guided surgery in primary hyperparathyroidism when ultrasound and MIBI SPECT/CT are negative or inconclusive: the APACH1 study. Eur J Nucl Med Mol Imaging. 2018;45:658–66. https://doi.org/10.1007/s00259-017-3911-1 .
doi: 10.1007/s00259-017-3911-1
pubmed: 29270788
Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S, Berdelou A, Hadoux J, Hescot S, Remy H, Baudin E, Schlumberger M, Deandreis D. Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of
doi: 10.1007/s00259-018-4018-z
pubmed: 29680989
Huber GF, Hüllner M, Schmid C, Brunner A, Sah B, Vetter D, Kaufmann PA, von Schulthess GK. Benefit of 18F-fluorocholine PET imaging in parathyroid surgery. Eur Radiol. 2018;28:2700–7. https://doi.org/10.1007/s00330-017-5190-4 .
doi: 10.1007/s00330-017-5190-4
pubmed: 29372312
Araz M, Soydal Ç, Özkan E, Kir MK, İbiş E, Güllü S, Erdoğan MF, Emral R, Küçük ÖN. The efficacy of fluorine-18-choline PET/CT in comparison with 99mTc-MIBI SPECT/CT in the localization of a hyperfunctioning parathyroid gland in primary hyperparathyroidism. Nucl Med Commun. 2018;39:989–94. https://doi.org/10.1097/MNM.0000000000000899 .
doi: 10.1097/MNM.0000000000000899
pubmed: 30138157
Piccardo A, Trimboli P, Rutigliani M, Puntoni M, Foppiani L, Bacigalupo L, Crescenzi A, Bottoni G, Treglia G, Paparo F, Del Monte P, Lanata M, Paone G, Ferrarazzo G, Catrambone U, Arlandini A, Ceriani L, Cabria M, Giovanella L. Additional value of integrated
doi: 10.1007/s00259-018-4147-4
pubmed: 30219964
Zajíčková K, Zogala D, Kubinyi J. Parathyroid imaging by (18)F-fluorocholine PET/CT in patients with primary hyperparathyroidism and inconclusive conventional methods: clinico-pathological correlations. Physiol Res. 2018;67:S551–7. https://doi.org/10.33549/physiolres.934029 .
doi: 10.33549/physiolres.934029
pubmed: 30484682
Fischli S, Suter-Widmer I, Nguyen BT, Müller W, Metzger J, Strobel K, Grünig H, Henzen C. The Significance of 18F-fluorocholine-PET/CT as localizing imaging technique in patients with primary hyperparathyroidism and negative conventional imaging. Front Endocrinol (Lausanne). 2017;8:380. https://doi.org/10.3389/fendo.2017.00380 .
doi: 10.3389/fendo.2017.00380
Lezaic L, Rep S, Sever MJ, Kocjan T, Hocevar M, Fettich J.
doi: 10.1007/s00259-014-2837-0
pubmed: 25063039
Rep S, Lezaic L, Kocjan T, Pfeifer M, Sever MJ, Simoncic U, Tomse P, Hocevar M. Optimal scan time for evaluation of parathyroid adenoma with [(18)F]-fluorocholine PET/CT. Radiol Oncol. 2015;49:327–33. https://doi.org/10.1515/raon-2015-0016 .
doi: 10.1515/raon-2015-0016
pubmed: 26834518
pmcid: 4722922
Hocevar M, Lezaic L, Rep S, Zaletel K, Kocjan T, Sever MJ, Zgajnar J, Peric B. Focused parathyroidectomy without intraoperative parathormone testing is safe after pre-operative localization with
doi: 10.1016/j.ejso.2016.09.016
pubmed: 27776943
Rep S, Hocevar M, Vaupotic J, Zdesar U, Zaletel K, Lezaic L.
doi: 10.1088/1361-6498/aaa86f
pubmed: 29339573
Alharbi AA, Alshehri FM, Albatly AA, Sah B-R, Schmid C, Huber GF, Huellner MW. [
doi: 10.1007/s11307-018-1179-x
pubmed: 29508264
Beheshti M, Hehenwarter L, Paymani Z, Rendl G, Imamovic L, Rettenbacher R, Tsybrovskyy O, Langsteger W, Pirich C. 18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients. Eur. J. Nucl. Med. Mol. Imaging. 2018;45:1762–71. https://doi.org/10.1007/s00259-018-3980-9 .
doi: 10.1007/s00259-018-3980-9
pubmed: 29516131
pmcid: 6097754
Bossert I, Chytiris S, Hodolic M, Croce L, Mansi L, Chiovato L, Mariani G, Trifirò G. PETC/CT with 18F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J Endocrinol Invest. 2019;42:419–26. https://doi.org/10.1007/s40618-018-0931-z .
doi: 10.1007/s40618-018-0931-z
pubmed: 30094743
Christakis I, Khan S, Sadler GP, Gleeson FV, Bradley KM, Mihai R. 18Fluorocholine PET/CT scanning with arterial phase-enhanced CT is useful for persistent/recurrent primary hyperparathyroidism: first UK case series results. Ann R Coll Surg Engl. 2019;101:501–7. https://doi.org/10.1308/rcsann.2019.0059 .
doi: 10.1308/rcsann.2019.0059
pubmed: 31305126
Thanseer NTK, Parihar AS, Sood A, Bhadada SK, Dahiya D, Singh P, Mittal BR. Evaluation of recurrent parathyroid carcinoma: a new imaging tool in uncommon entity. World J Nucl Med. 2018;18:198–200. https://doi.org/10.4103/wjnm.WJNM_67_18 .
doi: 10.4103/wjnm.WJNM_67_18
Broos WAM, van der Zant FM, Knol RJJ, Wondergem M. Choline PET/CT in parathyroid imaging: a systematic review. Nucl Med Commun. 2019;40:96–105. https://doi.org/10.1097/MNM.0000000000000952 .
doi: 10.1097/MNM.0000000000000952
pubmed: 30444749
Hansen BB, Hansen P, Nordberg CL, Boesen M. Imaging of the spine in cases of low back pain. Ugeskr Laeger. 2018;180(16):V06170475
pubmed: 29690989
Fukumoto M. Single-photon agents for tumor imaging: 201Tl, 99mTc-MIBI, and 99mTc-tetrofosmin. Ann Nucl Med. 2004;18:79–95. https://doi.org/10.1007/bf02985098 .
doi: 10.1007/bf02985098
pubmed: 15195755
Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med. 2007;37:400–19. https://doi.org/10.1053/j.semnuclmed.2007.08.004 .
doi: 10.1053/j.semnuclmed.2007.08.004
pubmed: 17920348
Ishizuka T, Kajita K, Kamikubo K, Komaki T, Miura K, Nagao S, Nozawa Y. Phospholipid/Ca2 + -dependent protein kinase activity in human parathyroid adenoma. Endocrinol Jpn. 1987;34:965–8. https://doi.org/10.1507/endocrj1954.34.965 .
doi: 10.1507/endocrj1954.34.965
pubmed: 3450512
Kim S-J, Lee S-W, Jeong SY, Pak K, Kim K. Diagnostic performance of F-18 fluorocholine PET/CT for parathyroid localization in hyperparathyroidism: a systematic review and meta-analysis. Horm Cancer. 2018;9:440–7. https://doi.org/10.1007/s12672-018-0347-4 .
doi: 10.1007/s12672-018-0347-4
pubmed: 30121878
Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, Giovanella L. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46:751–65. https://doi.org/10.1007/s00259-018-4123-z .
doi: 10.1007/s00259-018-4123-z
pubmed: 30094461
Boccalatte LA, Higuera F, Gómez NL, de la Torre AY, Mazzaro EL, Galich AM, Collaud C, Figari MF. Usefulness of 18F-fluorocholine positron emission tomography-computed tomography in locating lesions in hyperparathyroidism: a systematic review. JAMA Otolaryngol Head Neck Surg. 2019. https://doi.org/10.1001/jamaoto.2019.0574 .
doi: 10.1001/jamaoto.2019.0574
pubmed: 31145436
Johnson NA, Tublin ME, Ogilvie JB. Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. AJR Am J Roentgenol. 2007;188:1706–15. https://doi.org/10.2214/AJR.06.0938 .
doi: 10.2214/AJR.06.0938
pubmed: 17515397
Yildiz S, Aralasmak A, Yetis H, Kilicarslan R, Sharifov R, Alkan A, Toprak H. MRI findings and utility of DWI in the evaluation of solid parathyroid lesions. Radiol Med. 2019;124:360–7. https://doi.org/10.1007/s11547-018-0970-8 .
doi: 10.1007/s11547-018-0970-8
pubmed: 30607865
Starker LF, Mahajan A, Bjorklund P, Sze G, Udelsman R, Carling T. 4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol. 2011;18:1723–8.
doi: 10.1245/s10434-010-1507-0
Mekel M, Linder R, Bishara B, Kluger Y, Bar-On O, Fischer D. 4-dimensional computed tomography for localization of parathyroid adenoma. Harefuah. 2013;152:710–2.
pubmed: 24482992
Hamidi M, Sullivan M, Hunter G, Hamberg L, Cho NL, Gawande AA, et al. 4D-CT is superior to ultrasound and sestamibi for localizing recurrent parathyroid disease. Ann Surg Oncol. 2018;25(5):1403–9.
doi: 10.1245/s10434-018-6367-z
Tian Y, Tanny ST, Einsiedel P, Lichtenstein M, Stella DL, Phal PM, et al. Four-dimensional computed tomography: clinical impact for patients with primary hyperparathyroidism. Ann Surg Oncol. 2018;25:117–21.
doi: 10.1245/s10434-017-6115-9
Argirò R, Diacinti D, Sacconi B, Iannarelli A, Diacinti D, Cipriani C, Pisani D, Romagnoli E, Biffoni M, Di Gioia C, Pepe J, Bezzi M, Letizia C, Minisola S, Catalano C. Diagnostic accuracy of 3T magnetic resonance imaging in the preoperative localisation of parathyroid adenomas: comparison with ultrasound and 99mTc-sestamibi scans. Eur Radiol. 2018;28:4900–8. https://doi.org/10.1007/s00330-018-5437-8 .
doi: 10.1007/s00330-018-5437-8
pubmed: 29736849
Ozturk M, Polat AV, Celenk C, Elmali M, Kir S, Polat C. The diagnostic value of 4D MRI at 3T for the localization of parathyroid adenomas. Eur J Radiol. 2019;112:207–13. https://doi.org/10.1016/j.ejrad.2019.01.022 .
doi: 10.1016/j.ejrad.2019.01.022
pubmed: 30777212